DVT Prophylaxis in Patients Taking Prasugrel

Bleeding Risk Considerations

The American College of Cardiology notes that both prasugrel and enoxaparin independently increase bleeding risk through different mechanisms, with prasugrel inhibiting platelets and enoxaparin acting as an anticoagulant 1
The National Comprehensive Cancer Network guidelines indicate that when used together, these medications create a compounded bleeding risk that may outweigh the thromboprophylactic benefit in most clinical scenarios 2
According to Blood Advances, the risk of major bleeding increases approximately 2-fold when extended anticoagulation is added to existing antiplatelet therapy, with a relative risk of 1.99 and a 95% confidence interval of 1.08-3.65 3

For patients requiring DVT prophylaxis while on prasugrel, the American Urological Association recommends mechanical prophylaxis options, including intermittent pneumatic compression devices as first-line prophylaxis for patients with contraindications to pharmacological prophylaxis 4
The Society of Critical Care Medicine suggests that early ambulation should be implemented whenever possible, and that if pharmacological prophylaxis is absolutely necessary, consideration should be given to risk stratification based on indication for prasugrel, patient's baseline bleeding risk, and indication and urgency for DVT prophylaxis 5

The American College of Cardiology recommends assessing thrombotic risk by determining if the patient is low, moderate, high, or very high risk for VTE, and considering patient-specific factors such as immobility, cancer, and prior VTE 4
The National Comprehensive Cancer Network guidelines suggest assessing bleeding risk by considering factors such as age, renal dysfunction, and low body weight, and selecting prophylaxis based on risk assessment, with low VTE risk patients receiving early ambulation only, and moderate to high VTE risk patients with high bleeding risk receiving mechanical prophylaxis 2

The National Comprehensive Cancer Network guidelines recommend monitoring closely for signs of bleeding if enoxaparin must be used with prasugrel, and assessing renal function before initiating enoxaparin, with dose adjustments required for CrCl <30 mL/min 2
The Journal of the National Comprehensive Cancer Network suggests considering the timing of prasugrel administration relative to enoxaparin to minimize peak anticoagulant effects occurring simultaneously, and using the lowest effective dose of enoxaparin, such as 20mg daily rather than 40mg daily 1

Blood Advances notes that failing to recognize the additive bleeding risk of combined antiplatelet and anticoagulant therapy is a common pitfall, as is using standard DVT prophylaxis dosing without considering the patient's antiplatelet regimen, and not implementing appropriate mechanical prophylaxis when pharmacological options are contraindicated 3